论文部分内容阅读
根据世界心脏联盟调 查,全球有6亿高血压患者 面临发生心梗、脑卒中和心 力衰竭的危险,其中1.8亿 患者来自高收入国家,4.2 亿分布于中低收入国家。截 止到2000年,美国高血压的 控制率为34％,而我国的最 新资料显示仅有8.1％。所 以对心血管疾病的防治策 略应该以高血压为突破口, 预防和减少脑卒中、心肌梗 死等可能致残或致死的主 要不良心血管事件,综合防 治心血管疾病。海捷亚是近 几年开发研制出的固定处 方联合用药降低血压的药 物之一,受到了很多人的关 注。它与常规降压药以及常 规联合用药比较,优势究竟 在哪儿?如何正确使用? 带着诸多的疑惑,我们策划 了本期专家评药。
According to the World Heart Federation survey, 600 million hypertensive patients worldwide are at risk of developing MI, stroke and heart failure. Of these, 180 million are from high-income countries and 420 million are from low and middle-income countries. As of 2000, the control rate of hypertension in the United States was 34%, while the latest data from our country showed only 8.1%. Therefore, prevention and treatment of cardiovascular disease should be based on high blood pressure as a breakthrough to prevent and reduce stroke, myocardial infarction and other major disabling or lethal adverse cardiovascular events, comprehensive prevention and treatment of cardiovascular disease. Hytera is developed in recent years, a fixed combination of prescription drugs to lower blood pressure one of the drugs, has been a lot of people’s attention. It is compared with conventional antihypertensive drugs and conventional combination therapy, the advantages of exactly where? How to use correctly? With so many doubts, we planned the current expert evaluation of drugs.